Literature DB >> 27810707

A specific profile of luteal phase progesterone is associated with the development of premenstrual symptoms.

Thelma A Lovick1, Vinicius G Guapo2, Janete A Anselmo-Franci3, Camila M Loureiro2, Maria Clara M Faleiros2, Cristina M Del Ben2, Marcus L Brandão4.   

Abstract

There is a consensus that the development of premenstrual dysphoric states is related to cyclical change in gonadal hormone secretion during the menstrual cycle. However, results from studies seeking to link symptom severity to luteal phase progesterone concentration have been equivocal. In the present study we evaluated not only the absolute concentrations of progesterone but also the kinetics of the change in progesterone concentration in relation to development of premenstrual symptoms during the last 10days of the luteal phase in a population of 46 healthy young adult Brazilian women aged 18-39 years, mean 26.5±6.7years. In participants who developed symptoms of premenstrual distress, daily saliva progesterone concentration remained stable during most of the mid-late luteal phase, before declining sharply during the last 3days prior to onset of menstruation. In contrast, progesterone concentration in asymptomatic women underwent a gradual decline over the last 8days prior to menstruation. Neither maximum nor minimum concentrations of progesterone in the two groups were related to the appearance or severity of premenstrual symptoms. We propose that individual differences in the kinetics of progesterone secretion and/or metabolism may confer differential susceptibility to the development of premenstrual syndrome. Crown Copyright Â
© 2016. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Luteal phase; Premenstrual symptoms; Progesterone; Saliva

Mesh:

Substances:

Year:  2016        PMID: 27810707     DOI: 10.1016/j.psyneuen.2016.10.024

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  15 in total

Review 1.  Progesterone, reproduction, and psychiatric illness.

Authors:  Lindsay R Standeven; Katherine O McEvoy; Lauren M Osborne
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2020-06-18       Impact factor: 5.237

2.  Are there temporal subtypes of premenstrual dysphoric disorder?: using group-based trajectory modeling to identify individual differences in symptom change.

Authors:  Tory A Eisenlohr-Moul; Gudrun Kaiser; Cornelia Weise; Katja M Schmalenberger; Jeff Kiesner; Beate Ditzen; Maria Kleinstäuber
Journal:  Psychol Med       Date:  2019-04-23       Impact factor: 10.592

3.  Effects of Estrogen Therapy on the Serotonergic System in an Animal Model of Perimenopause Induced by 4-Vinylcyclohexen Diepoxide (VCD).

Authors:  Nayara Pestana-Oliveira; Bruna Kalil; Cristiane Mota Leite; Ruither Oliveira Gomes Carolino; Lucas Kniess Debarba; Lucila Leico Kagohara Elias; José Antunes-Rodrigues; Janete A Anselmo-Franci
Journal:  eNeuro       Date:  2018-01-22

4.  Lowered Plasma Steady-State Levels of Progesterone Combined With Declining Progesterone Levels During the Luteal Phase Predict Peri-Menstrual Syndrome and Its Major Subdomains.

Authors:  Chutima Roomruangwong; André F Carvalho; Frank Comhaire; Michael Maes
Journal:  Front Psychol       Date:  2019-10-30

5.  Early- and Late-Luteal-Phase Estrogen and Progesterone Levels of Women with Premenstrual Dysphoric Disorder.

Authors:  Ju-Yu Yen; Huang-Chi Lin; Pai-Cheng Lin; Tai-Ling Liu; Cheng-Yu Long; Chih-Hung Ko
Journal:  Int J Environ Res Public Health       Date:  2019-11-07       Impact factor: 3.390

6.  Comparison of serum level of some trace elements and vitamin D between patients with premenstrual syndrome and normal controls: A cross-sectional study.

Authors:  Mahnoosh Fatemi; Maryam Allahdadian; Mehrnoosh Bahadorani
Journal:  Int J Reprod Biomed       Date:  2019-09-22

Review 7.  How to study the menstrual cycle: Practical tools and recommendations.

Authors:  Katja M Schmalenberger; Hafsah A Tauseef; Jordan C Barone; Sarah A Owens; Lynne Lieberman; Marc N Jarczok; Susan S Girdler; Jeff Kiesner; Beate Ditzen; Tory A Eisenlohr-Moul
Journal:  Psychoneuroendocrinology       Date:  2020-10-13       Impact factor: 4.905

8.  Insomnia, Inattention and Fatigue Symptoms of Women with Premenstrual Dysphoric Disorder.

Authors:  Pai-Cheng Lin; Chih-Hung Ko; Yen-Ju Lin; Ju-Yu Yen
Journal:  Int J Environ Res Public Health       Date:  2021-06-08       Impact factor: 3.390

9.  Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle.

Authors:  Liisa Hantsoo; C Neill Epperson
Journal:  Neurobiol Stress       Date:  2020-02-04

10.  Endocrine profile of the VCD-induced perimenopausal model rat.

Authors:  Ruither O G Carolino; Paulo T Barros; Bruna Kalil; Janete Anselmo-Franci
Journal:  PLoS One       Date:  2019-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.